Lucera Erick
Chief Financial Officer
Lucera Erick has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Aug 17, 2026.
On the most recent filing, Lucera Erick is listed as Chief Financial Officer at Dyne Therapeutics, Inc. Inside the rolling window, Lucera Erick reported no open-market purchases and 4 open-market sales totaling $229K in DYN. The largest disclosed transaction in the window is a sale of 5,727 DYN shares on Apr 1, 2026, worth $107K.
Companies traded
Other insiders at DYN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$229K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lucera Erick made?
Lucera Erick has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Lucera Erick trade?
Lucera Erick has filed SEC Form 4 disclosures for 1 company, including DYN.
When was Lucera Erick's most recent SEC Form 4 filing?
Lucera Erick's most recent SEC Form 4 filing on Tracefour is dated Aug 17, 2026.
What is Lucera Erick's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lucera Erick is listed as Chief Financial Officer.
What is Lucera Erick's total buy and sell value in the current window?
Inside the rolling retention window, Lucera Erick bought $0 and sold $229K based on SEC Form 4 filings.
What was Lucera Erick's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 5,727 DYN shares on 2026-04-01, worth $107K, per SEC Form 4 filings.